InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

- Current share price for RAD : $0.011

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$48 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2025 9:55AM $0.022 $0.011 fallen by 50%
$48 RAD receives IND approval from US FDA for Betabart (RV-01) 28 Jul 2025 8:26AM $0.023 $0.011 fallen by 52.17%
$48 Dr Oliver Sartor appointed to RAD Scientific Advisory Board 22 Jul 2025 8:30AM $0.023 $0.011 fallen by 52.17%
$48 Radiopharm Receives $4.5M R&D Tax Incentive 16 Jul 2025 9:01AM $0.022 $0.011 fallen by 50%
$48 RAD and Cyclotek Sign Supply Agreement for 161Tb-KLK3-mAb 24 Jun 2025 9:35AM $0.023 $0.011 fallen by 52.17%
$48 Change in substantial holding 16 Jun 2025 4:56PM $0.026 $0.011 fallen by 57.69%
$48 Notice Under Section 708A 12 Jun 2025 8:30AM $0.026 $0.011 fallen by 57.69%
$48 Application for quotation of securities - RAD 12 Jun 2025 8:24AM $0.026 $0.011 fallen by 57.69%
$48 RAD Granted US FDA Fast Track for RAD101 Metastases Imaging 11 Jun 2025 8:24AM $0.024 $0.011 fallen by 54.17%
$48 Proposed issue of securities - RAD 10 Jun 2025 5:35PM $0.024 $0.011 fallen by 54.17%
$48 RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202 4 Jun 2025 8:26AM $0.026 $0.011 fallen by 57.69%
$48 RAD Reports Positive Preclinical Lu177-B7H3-mAb Data 2 Jun 2025 9:14AM $0.024 $0.011 fallen by 54.17%
$48 Change of Director's Interest Notice (IT) 30 May 2025 6:37PM $0.024 $0.011 fallen by 54.17%
$48 ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177 19 May 2025 8:23AM $0.022 $0.011 fallen by 50%
$48 Acceleration of RAD204 Phase 1 dose escalation trial 12 May 2025 8:46AM $0.022 $0.011 fallen by 48.84%
$48 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 10:15AM $0.022 $0.011 fallen by 50%
$48 First patient dosed in Phase IIb imaging for Brain Mets 28 Apr 2025 9:29AM $0.021 $0.011 fallen by 47.62%
$48 New RAD202 data confirms positive tumor uptake 17 Mar 2025 9:28AM $0.028 $0.011 fallen by 60.71%
$48 Participation in Leerink, NWR healthcare conferences 13 Mar 2025 8:22AM $0.027 $0.011 fallen by 59.26%
$48 Update - Notification regarding unquoted securities - RAD 7 Mar 2025 9:12AM $0.032 $0.011 fallen by 65.63%
$48 Notification regarding unquoted securities - RAD 7 Mar 2025 9:05AM $0.032 $0.011 fallen by 65.63%
$48 Half Year Report and Appendix 4D 31 December 2024 28 Feb 2025 5:10PM $0.026 $0.011 fallen by 57.69%
$48 Notification of cessation of securities - RAD 25 Feb 2025 8:34AM $0.024 $0.011 fallen by 54.17%
$48 Change of Director's Interest Notice (IT) 25 Feb 2025 8:26AM $0.024 $0.011 fallen by 54.17%
$48 RAD to present at TD Cowen Annual Healthcare Conference 24 Feb 2025 11:08AM $0.024 $0.011 fallen by 54.17%

101 - 125 of 612 results

Page 5 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.